Skip to main content

Table 2 Effectiveness of DDR deficiencies in predicting ICI efficacy in solid tumors

From: The role of DNA damage repair (DDR) system in response to immune checkpoint inhibitor (ICI) therapy

Clinical endpoint DDR deficiency ICI Cancer type Proficiency type Deficiency type Refs
ORR HR Nivolumab+ipilimumab Prostate cancer 22.6% 50.0% [13]
DDR positive Nivolumab+ipilimumab Prostate cancer 23.1% 36.4% [13]
DDR positive ICI Prostate cancer 20.0% 40.0% [48]
MMR Pembrolizumab Colorectal cancer 0.0% 40.0% [24]
PFS MMR Pembrolizumab Colorectal cancer 2.2 m NR [24]
OS MMR Pembrolizumab Colorectal cancer 5.0 m NR [24]
HR Nivolumab+ipilimumab Prostate cancer 19.0 m NR [13]
  1. Abbreviations: ORR Objective response rate, PFS Progression-free survival, OS Overall survival, NR Not reached